CytoDel Overview

  • Founded

  • 2012

Founded
  • Status

  • Private

  • Employees

  • 6

Employees
  • Latest Deal Type

  • Grant

  • Latest Deal Amount

  • $277K

  • Investors

  • 3

CytoDel General Information

Description

Provider of a biotechnology platform intended to produce recombinant derivatives of botulinum neurotoxin (BoNT). The company's platform manipulates the BoNT molecule into a drug delivery vehicle that can deliver therapeutic molecules to the inside of neurons with important implications, enabling medical researchers to develop drugs and facilitate the treatment of nervous system disorders, chronic pain, and neurodegenerative diseases.

Contact Information

Website
www.cytodel.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • 423 West 127th Street
  • New York, NY 10027
  • United States
+1 (501) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

CytoDel Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Grant 01-Mar-2022 $277K 00.00 Completed Pre-Clinical Trials
5. Accelerator/Incubator 00.00 Completed Pre-Clinical Trials
4. Later Stage VC (Series A) 16-Jan-2018 00.00 00.00 000.00 Completed Pre-Clinical Trials
3. Grant 01-Jul-2017 000.00 Completed Pre-Clinical Trials
2. Grant 01-Jan-2014 $224K Completed Pre-Clinical Trials
1. Accelerator/Incubator 13-Dec-2013 Completed Pre-Clinical Trials
To view CytoDel’s complete valuation and funding history, request access »

CytoDel Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series A-1 0,000,000 00.000000 00.00 00.00 00 00.00 00.00
Series A-2 000,000 00.000000 00.00 00.00 00 00.00 00
To view CytoDel’s complete cap table history, request access »

CytoDel Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Provider of a biotechnology platform intended to produce recombinant derivatives of botulinum neurotoxin (BoNT). The com
Drug Discovery
New York, NY
6 As of 2023
00.00
0000000000 00.00

000000

t aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in vol
0000000000000
Cambridge, MA
0000 As of 0000
000.00
000 0000-00-00
000000&0

000000

olor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut
0000 000000000
North Chicago, IL
00000 As of 0000
00.000
00000000000 00.000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

CytoDel Competitors (5)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Biogen Formerly VC-backed Cambridge, MA 0000 000.00 000000&0
000000 Corporation North Chicago, IL 00000 00.000 00000000000 00.000
000 00000 Corporation Indianapolis, IN 00000 000000 - 000
00000 Formerly PE-Backed Thousand Oaks, CA 00000 00.000 000000000000 00.000
0000 000000 Corporation Frankfurt, Germany 0000
You’re viewing 5 of 5 competitors. Get the full list »

CytoDel Executive Team (3)

Name Title Board Seat Contact Info
Philip Band Ph.D Co-Founder, Chief Executive Officer & Board Member
Konstantin Ichtchenko Ph.D Co-Founder, CSO and Founding Scientist
You’re viewing 2 of 3 executive team members. Get the full list »

CytoDel Board Members (6)

Name Representing Role Since
André Gudger CytoDel Board Member 000 0000
Dennis Huang CytoDel Board Member 000 0000
Lawrence Remmel JD Self Board Member 000 0000
Margery Fischbein Self Board Member 000 0000
Philip Band Ph.D CytoDel Co-Founder, Chief Executive Officer & Board Member 000 0000
You’re viewing 5 of 6 board members. Get the full list »

CytoDel Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

CytoDel Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
NYU Entrepreneurial Institute Accelerator/Incubator Minority 000 0000 000000 0
National Institutes of Health Government 000 0000 000000 0
U.S. Department of Health and Human Services Government 000 0000 000000 0
To view CytoDel’s complete investors history, request access »

Ready to get started?

Request a free trial